<DOC>
	<DOC>NCT00006394</DOC>
	<brief_summary>OBJECTIVES: I. Compare whether the bone tissue in the spine and hip improves in patients with adult onset growth hormone deficiency treated with growth hormone (GH) vs placebo. II. Determine whether the blood samples of these patients show evidence of beneficial bone effects after treatment with GH. III. Compare the quality of life of these patients treated with these 2 regimens. IV. Determine the side effects of GH in these patients.</brief_summary>
	<brief_title>Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive growth hormone subcutaneously (SC) daily for 2 years. Arm II: Patients receive placebo SC daily for 2 years. Quality of life is assessed at the initial eligibility screening, then again within 1 month after the initial screening, and then at 1, 3, and 6 months during study therapy.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Diagnosis of adult onset growth hormone deficiency Patient Characteristics Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>disease-related problem/condition</keyword>
	<keyword>endocrine disorders</keyword>
	<keyword>growth hormone deficiency</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>quality of life</keyword>
	<keyword>rare disease</keyword>
</DOC>